Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | BCL2 | P10415 | 3/20 | 0.46 |
| ▸ | BCL2L2 | Q92843 | 3/20 | 0.46 |
| ▸ | BAD | Q92934 | 3/20 | 0.46 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL316517 | 0.84 | L3MBTL1 (0.38) | L3MBTL1ALDH1A1GAAKMT2APOLB | |
| SCHEMBL10037556 | 0.81 | L3MBTL1 (0.37) | L3MBTL1ALDH1A1GAAKMT2APOLB | |
| SCHEMBL316509 | 0.78 | L3MBTL1 (0.35) | L3MBTL1ALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL4481252 | 0.75 | ALDH1A1 (0.74) | L3MBTL1ALDH1A1GAAKMT2APOLB | |
| SCHEMBL13919544 | 0.75 | ALDH1A1 (0.74) | L3MBTL1ALDH1A1GAAKMT2APOLB | |
| SCHEMBL2267205 | 0.71 | TDP1 (0.46) | L3MBTL1ALDH1A1TDP1TSHR | |
| SCHEMBL6307495 | 0.71 | POLB (0.60) | L3MBTL1ALDH1A1GAAKMT2APOLB | |
| SCHEMBL6307483 | 0.71 | POLB (0.60) | L3MBTL1ALDH1A1GAAKMT2APOLB | |
| SCHEMBL478614 | 0.69 | ALDH1A1 (1.00) | L3MBTL1ALDH1A1GAAKMT2APOLB | |
| SCHEMBL4861809 | 0.69 | ALDH1A1 (1.00) | L3MBTL1ALDH1A1GAAKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2045014-B1 | POLYMER-SUPPORTED METAL COMPLEX CATALYST | UNIV HOKKAIDO NAT UNIV CORP (JP) | 2014-01-15 | — | — | EP | disclosed |
| US-8092720-B2 | Polymer-supported metal complex catalyst | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2012-01-10 | — | — | US | disclosed |
| US-20090227743-A1 | POLYMER-SUPPORTED METAL COMPLEX CATALYST | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2009-09-10 | — | — | US | disclosed |
| EP-2045014-A1 | POLYMER-SUPPORTED METAL COMPLEX CATALYST | National University Corporation Hokkaido University (JP) | 2009-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227743-A1 | POLYMER-SUPPORTED METAL COMPLEX CATALYST | PYM1, ARG1, SCO2 | L3MBTL1 2735/4885ALDH1A1 2736/4885GAA 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.